The measurement of symptoms and side effects in clinical trials of chronic pain

Contemporary Clinical Trials

Volumn 33, Issue 5, 2012, Pages 903-911

  Katz, Nathaniel P ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Analgesic Solutions   (United States)

Author keywords

Opioids; Pain; Scales; Signs; Symptoms; Trials

Indexed keywords

MORPHINE; NAPROXEN; OXYCODONE PLUS PARACETAMOL;

CHRONIC PAIN; DISTRESS SYNDROME; DRUG DOSE TITRATION; DRUG TOLERABILITY; HUMAN; LOW BACK PAIN; METHODOLOGY; OPEN-ENDED QUESTIONNAIRE; PASSIVE CAPTURE OF ADVERSE EVENT; PROSPECTIVE ASSESSMENT OF SPECIFIC SIDE EFFECTS OF INTERE; PROSPECTIVE COMPREHENSIVE SYMPTOM CHECKLIST; QUALITY OF LIFE; REVIEW; SCRIPTED PROMPTING;

CHRONIC PAIN; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DRUG TOXICITY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84864304171     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.04.008     Document Type: Review

References (56)

1. Collins S.L., Edwards J., Moore R.A., Smith L.A., McQuay H.J. Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?. Pain 2001, 91(1-2):189-194.
2. Stedman's Medical Dictionary 2000, Lippincott, Williams & Wilkins, Philadelphia. 27 ed. T. Stedman (Ed.).
3. Rhodes V.A., McDaniel R.W., Homan S.S., Johnson M., Madsen R. An instrument to measure symptom experience. Symptom occurrence and symptom distress. Cancer Nurs 2000, 23(1):49-54.
4. Rhodes V.A., Watson P.M. Symptom distress - the concept: past and present. Semin Oncol Nurs 1987, 3(4):242-247.
5. Gracely R.H., Dubner R., McGrath P.A. Fentanyl reduces the intensity of painful tooth pulp sensations: controlling for detection of active drugs. Anesth Analg 1982, 61(9):751-755.
6. Gracely R.H., McGrath P., Dubner R. Validity and sensitivity of ratio scales of sensory and affective verbal pain descriptors: manipulation of affect by diazepam. Pain 1978, 5(1):19-29.
7. Tishelman C., Degner L.F., Mueller B. Measuring symptom distress in patients with lung cancer. A pilot study of experienced intensity and importance of symptoms. Cancer Nurs 2000, 23(2):82-90.
8. Tishelman C., Taube A., Sachs L. Self-reported symptom distress in cancer patients: reflections of disease, illness or sickness?. Soc Sci Med 1991, 33(11):1229-1240.
9. Edwards J.E., McQuay H.J., Moore R.A., Collins S.L. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage 1999, 18(6):427-437.
10. Loke Y.K., Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol 2001, 1(1):3.
11. Ward S.E., Goldberg N., Miller-McCauley V., Mueller C., Nolan A., Pawlik-Plank D., et al. Patient-related barriers to management of cancer pain. Pain 1993, 52(3):319-324.
12. Frank L., Kleinman L., Farup C., Taylor L., Miner P. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999, 34(9):870-877.
13. Damiano A., Handley K., Adler E., Siddique R., Bhattacharyja A. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002, 47(7):1530-1537.
14. Katz N., Ju W.D., Krupa D.A., Sperling R.S., Bozalis Rodgers D., Gertz B.J., et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine May 1 2003, 28(9):851-858.
15. Revicki D.A., Wood M., Wiklund I., Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998, 7(1):75-83.
16. Rothman M., Farup C., Stewart W., Helbers L., Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001, 46(7):1540-1549.
17. Watson D.J., Harper S.E., Zhao P.L., Quan H., Bolognese J.A., Simon T.J. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000, 160(19):2998-3003.
18. Chiou C.P. Development and psychometric assessment of the physical symptom distress scale. J Pain Symptom Manage 1998, 16(2):87-95.
19. Anderson R.B., Hollenberg N.K., Williams G.H. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med 1999, 159(7):693-700.
20. Testa M.A., Hollenberg N.K., Anderson R.B., Williams G.H. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991, 4(4 Pt 1):363-373.
21. Testa M.A., Anderson R.B., Nackley J.F., Hollenberg N.K. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N Engl J Med 1993, 328(13):907-913.
22. Cleeland C.S., Mendoza T.R., Wang X.S., Chou C., Harle M.T., Morrissey M., et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000, 89(7):1634-1646.
23. Chang V.T., Hwang S.S., Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000, 88(9):2164-2171.
24. Chang V.T., Hwang S.S., Feuerman M., Kasimis B.S. Symptom and quality of life survey of medical oncology patients at a Veterans Affairs Medical Center: a role for symptom assessment. Cancer 2000, 88(5):1175-1183.
25. Chang V.T., Hwang S.S., Feuerman M., Kasimis B.S., Thaler H.T. The memorial symptom assessment scale short form (MSAS-SF). Cancer 2000, 89(5):1162-1171.
26. Chang V.T., Thaler H.T., Polyak T.A., Kornblith A.B., Lepore J.M., Portenoy R.K. Quality of life and survival: the role of multidimensional symptom assessment. Cancer 1998, 83(1):173-179.
27. Samarel N., Leddy S.K., Greco K., Cooley M.E., Torres S.C., Tulman L., et al. Development and testing of the symptom experience scale. J Pain Symptom Manage 1996, 12(4):221-228.
28. Vogl D., Rosenfeld B., Breitbart W., Thaler H., Passik S., McDonald M., et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999, 18(4):253-262.
29. Jamison R.N., Raymond S.A., Slawsby E.A., Nedeljkovic S.S., Katz N.P. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998, 23(23):2591-2600.
30. Anderson R. What does it mean?: anchoring psychosocial quality of life scale score changes with reference to concurrent changes in reported symptom distress. Drug Inf J 1999, 33:445-453.
31. Hollenberg N.K., Williams G.H., Anderson R. Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. Arch Intern Med 2000, 160(10):1477-1483.
32. Anderson R., Testa M.A. Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Inf J 1994, 28:89-114.
33. Testa M.A. Parallel perspectives on quality of life during antihypertensive therapy: impact of responder, survey environment, and questionnaire structure. J Cardiovasc Pharmacol 1993, 21(Suppl. 2):S18-S25.
34. McClement S.E., Woodgate R.L., Degner L. Symptom distress in adult patients with cancer. Cancer Nurs 1997, 20(4):236-243.
35. Ganz P.A., Lee J.J., Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991, 67(12):3131-3135.
36. Coates A., Gebski V., Bishop J.F., Jeal P.N., Woods R.L., Snyder R., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987, 317(24):1490-1495.
37. Degner L.F., Sloan J.A. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 1995, 10(6):423-431.
38. Kaasa S., Mastekaasa A., Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol 1989, 15(3):235-242.
39. Kukull W., McCorkle R., Driever M. Symptom distress, psychosocial variables, and survival from lung cancer. J Psychosoc Oncol 1986, 4(1-2):91-104.
40. Ruckdeschel J., Piantadosi S. Quality of life assessment in lung surgery for bronchogenic carcinoma. Theor Surg 1991, 6:201-205.
41. Tamburini M., Brunelli C., Rosso S., Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996, 11(1):32-41.
42. Germino B.B. Symptom distress and quality of life. Semin Oncol Nurs 1987, 3(4):299-302.
43. Graf W., Glimelius B., Påhlman L., Bergström R. Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991, 27(9):1119-1123.
44. Bruera E., Miller M.J., Kuehn N., MacEachern T., Hanson J. Estimate of survival of patients admitted to a palliative care unit: a prospective study. J Pain Symptom Manage 1992, 7(2):82-86.
45. Earlam S., Glover C., Fordy C., Burke D., Allen-Mersh T.G. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996, 14(1):171-175.
46. Smith T.J., Staats P.S., Deer T., Stearns L.J., Rauck R.L., Boortz-Marx R.L., et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20(19):4040-4049.
47. Frishman W.H., Glasser S., Stone P., Deedwania P.C., Johnson M., Fakouhi T.D. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999, 83(4):507-514.
48. Von Roenn J.H., Cleeland C.S., Gonin R., Hatfield A.K., Pandya K.J. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993, 119(2):121-126.
49. Phillips D.M. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 2000, 284(4):428-429.
50. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362(10):865-869.
51. US Department of Health Human Services Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims 2011, FDA, Center for Drug Evaluation and Research, Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed April 15, 2011.
52. Jamison R.N., Raymond S.A., Levine J.G., Slawsby E.A., Nedeljkovic S.S., Katz N.P. Electronic diaries for monitoring chronic pain: 1-year validation study. Pain 2001, 91(3):277-285.
53. de Haes J.C., van Knippenberg F.C., Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990, 62(6):1034-1038.
54. McCorkle R., Young K. Development of a symptom distress scale. Cancer Nurs 1978, 1(5):373-378.
55. Portenoy R.K., Thaler H.T., Kornblith A.B., Lepore J.M., Friedlander-Klar H., Kiyasu E., et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994, 30A(9):1326-1336.
56. Bruera E., Kuehn N., Miller M.J., Selmser P., Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991, 7(2):6-9.